Loading
Life sciences · Journal article
Pharmacological Reports · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The endocannabinoid system (ECS) is a highly plastic signaling network whose components are dynamically regulated in a context-dependent manner. Among its components, the cannabinoid type 1 receptor (CB1R), encoded by the CNR1 gene, is involved in multiple processes, including neuromodulation, neurodevelopment, metabolic regulation, nociception, appetite regulation, redox homeostasis, and inflammatory signaling. Alterations in CB1R expression occur selectively and progressively and have been linked to numerous metabolic disorders, cancer, and neurodegenerative diseases. Recent studies have begun to unveil the transcriptional and epigenetic mechanisms regulating CB1R expression, involving inflammatory transcription factors, nuclear receptors, metabolic regulators, redox-sensitive pathways, hormone-responsive factors, as well as chromatin remodeling marks and promoter methylation. These modulatory programs collectively shape CB1R abundance and availability and may critically influence the efficacy and safety of cannabinoid-based therapies. In this review, we discuss current knowledge of the transcriptional and epigenetic regulation of the CNR1 gene in response to various pathologies and drugs, highlighting context-dependent modulatory mechanisms. Additionally, we performed an in silico analysis to identify potential transcription factor binding sites (TFBS) in the CNR1 promoter and to elucidate candidate regulatory networks underlying its differential expression in health and disease.